AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

American Journal of Public Health, Vol. 78, Issue 4 450-454, Copyright © 1988 by American Public Health Association

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eisenstaedt, R S
Right arrow Articles by Getzen, T E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eisenstaedt, R S
Right arrow Articles by Getzen, T E
Screening blood donors for human immunodeficiency virus antibody: cost-benefit analysis.

R S Eisenstaedt and T E Getzen

Department of Medicine, Temple University School of Medicine, Philadelphia, PA.

The costs and benefits of screening blood donors for antibody to human immunodeficiency virus (HIV) are assessed. Total costs, including testing, discarding processed blood, marginal donor recruiting, notifying and evaluating positive donors, are $36,234,000 annually for 10 million donors in 1986. Screening these donors will prevent 292 cases of transfusion-transmitted acquired immune deficiency syndrome (TT-AIDS), saving the costs of therapy and loss of earnings for total benefits of $43,490,480, a benefit:cost ratio of 1.2:1. Net economic benefits of $0.73 per donor will arise from the program. Calculated benefits will rise as increased numbers of infected recipients are diagnosed with longer follow-up or as partially effective therapy increases the cost of caring for patients with AIDS. Changes in test sensitivity, follow-up procedures, estimated value of life, and testing costs will also alter these projections, but none as dramatically as a change in the overall specificity of the screening process. The cost per case of TT-AIDS prevented, $124,089, and cost per year of life extended, $10,885, are comparable to costs of other screening programs.




This article has been cited by other articles:


Home page
 Med Decis MakingHome page
J. Hornberger, M. Holodniy, K. Robertus, M. Winnike, E. Gibson, and E. Verhulst
A Systematic Review of Cost-Utility Analyses in HIV/AIDS: Implications for Public Policy
Med Decis Making, December 1, 2007; 27(6): 789 - 821.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
A. B. Rosen, V. G. Fowler Jr., G. R. Corey, S. M. Downs, A. K. Biddle, J. Li, and J. G. Jollis
Cost-Effectiveness of Transesophageal Echocardiography To Determine the Duration of Therapy for Intravascular Catheter-Associated Staphylococcus aureus Bacteremia
Ann Intern Med, May 18, 1999; 130(10): 810 - 820.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
G. van den BOOM, C. P. van SCHAYCK, M. P. M. H. RUTTEN-van MOLKEN, P. R. S. TIRIMANNA, J. J. den OTTER, P. M. van GRUNSVEN, M. J. BUITENDIJK, C. L. A. van HERWAARDEN, and C. van WEEL
Active Detection of Chronic Obstructive Pulmonary Disease and Asthma in the General Population . Results and Economic Consequences of the DIMCA Program
Am. J. Respir. Crit. Care Med., December 1, 1998; 158(6): 1730 - 1738.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by the American Public Health Association